The Clinical Trials Network has two new locations participating in the Study of Fluoxetine in Autism (SOFIA): the University of South Florida, in Tampa, Florida and the Clinical Research Center of New Jersey (CRCNJ) in Voorhees, New Jersey.
The goal of the study is to evaluate the effectiveness of a new formulation of the medication in reducing repetitive behaviors. The SOFIA study features a melt-in-the-mouth formulation designed specifically for children and adolescents with autism. Neuropharm, the sponsor of the study, is seeking an FDA indication for the drug for treating this core symptom of autism.
All participating sites are currently enrolling children and adolescents between the ages of 5 and 17 years diagnosed with autistic disorder.
Interested parents can contact email@example.com or call 1-877-SOFIA-91 (1-877-763-4291) for more information.
Interested families in the Florida area can contact RothmanCtr@health.usf.edu or call 1-727-767-8393
Further information about the SOFIA program including links to the answers to frequently asked questions can be found on the Autism Speaks website. Visit the FAQ page here.
More detailed information about the study as well as a list of participating sites may be found on the U.S National Institutes of Health website by clicking here.
Read an article with more information on the study's FDA indication here.